✦ LIBER ✦

Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII

✍ Scribed by E. T. Parker; H. N. Craddock; R. T. Barrow; P. Lollar

Book ID: 109148320
Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 244 KB
Volume: 2
Category: Article
ISSN: 1538-7933
DOI: 10.1111/j.1538-7836.2004.00685.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Influence of aggregation on immunogenici

Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice

✍ Vivek S. Purohit; C. Russell Middaugh; Sathyamangalam V. Balasubramanian 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB

Recombinant human factor VIII (rFVIII), a multidomain glycoprotein is used in replacement therapy for treatment of hemophilia A. Unfortunately, 15%-30% of the treated patients develop inhibitory antibodies. The pathogenesis of antibody development is not completely understood. The presence of aggreg

Effect of route of administration of hum

Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice

✍ Aaron Peng; Puneet Gaitonde; Matthew P. Kosloski; Razvan D. Miclea; Prashant Var 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB

Factor VIII is a multi-domain glycoprotein and is an essential cofactor in the blood coagulation cascade. Its deficiency or dysfunction causes Hemophilia A, a bleeding disorder. Replacement using exogenous recombinant Factor VIII (FVIII) is the first line of therapy for Hemophilia A. Immunogenicity,

Phosphatidylserine containing liposomes

Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A

✍ Karthik Ramani; Razvan D. Miclea; Vivek S. Purohit; Donald E. Mager; Robert M. S 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 257 KB

Factor VIII (FVIII) is a multidomain protein that is deficient in hemophilia A, a clinically important bleeding disorder. Replacement therapy using recombinant human FVIII (rFVIII) is the main therapy. However, approximately 15-30% of patients develop inhibitory antibodies that neutralize rFVIII act

Efficacy and inhibitor development in pr

Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII

✍ Alessandro Gringeri; Annarita Tagliaferri; Giuseppe Tagariello; Massimo Morfini; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

Continuous infusion of B-domain deleted

Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience

✍ N. Stieltjes; C. Altisent; G. Auerswald; C. Négrier; P. Pouzol; J. Reynaud; V. R 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

The safety and efficacy of B-domain dele

The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update

✍ J. M. Lusher; D. A. Roth 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 29 KB